To identify whether serum CMTM2 could be abnormally altered in patients with HBV-related liver diseases, we analyzed CMTM2 levels in four groups, including CHB, HBLC, HCC and healthy individuals. This evidence concerns the gene CMTM2 and hepatocellular carcinoma.